FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285725> ?p ?o ?g. }

• W4379285725 endingPage "e13655" @default.
• W4379285725 startingPage "e13655" @default.
• W4379285725 abstract "e13655 Background: Over the past decades, US congress enabled the US Food and Drug Administration (FDA) to facilitate and expedite drug development for serious conditions filling unmet medical needs with five special designations: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. It remains unclear whether multiple designations per indication are redundant. This study analyzes cancer drugs with multiple special designations regarding their FDA approval timelines, evidence, benefit, epidemiology and price. Methods: All anti-cancer drugs and their supplemental indication approvals were identified in the Drugs@FDA database from 2000 to 2022. For each indication, clinical trial characteristics, epidemiologic, and price data were collected from FDA labels, the Global Burden of Disease Study, and Medicare & Medicaid Part B and D, respectively. The association between overall survival (OS) and progression-free survival (PFS) hazard ratios (HR) and drug indications’ number of special designations were compared in meta-analyses and meta-regressions. Results: We identified 170 anti-cancer drugs with FDA approval in 455 indications. The median time to first FDA approval was 13.8 years for drugs with zero, 7.3 years with one, 7.1 years with two, 7.8 with three, 5.8 with four, and 5.3 with five special designations (HR per additional designation: 1.27, 95%CI: 1.09-1.48, p=.002). Drug indications with more special designations were more frequently granted to rare diseases with fewer treatment options supported by smaller and shorter open-label phase 1/2 trials. OS HRs were 0.79 for indications with zero, 0.74 with one, 0.73 with two, 0.69 with three, 0.59 with four, and 0.52 with five special designations (p=.024). On average, each additional special designation was associated with lower HRs for OS (ß=-0.03, p=.002) and PFS (ß=-0.07, p<.001). Each additional special designation was associated with a 19.05% (95%CI: 4.56-35.55, p=.013) higher drug price. Conclusions: The FDA’s special designations are non-redundant. Multiple special designations are associated with faster approval times and a greater efficacy for patients with high unmet needs, while multiple special designations are associated with less robust trial evidence and higher drug prices. This study supports the strategy of special FDA designations for unmet clinical needs." @default.
• W4379285725 created "2023-06-05" @default.
• W4379285725 creator A5000839870 @default.
• W4379285725 creator A5018170393 @default.
• W4379285725 creator A5033869278 @default.
• W4379285725 creator A5068044534 @default.
• W4379285725 creator A5071104146 @default.
• W4379285725 creator A5074524521 @default.
• W4379285725 date "2023-06-01" @default.
• W4379285725 modified "2023-10-14" @default.
• W4379285725 title "Clinical evidence and benefit of special FDA designations in anti-cancer drugs." @default.
• W4379285725 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e13655" @default.
• W4379285725 hasPublicationYear "2023" @default.
• W4379285725 type Work @default.
• W4379285725 citedByCount "0" @default.
• W4379285725 crossrefType "journal-article" @default.
• W4379285725 hasAuthorship W4379285725A5000839870 @default.
• W4379285725 hasAuthorship W4379285725A5018170393 @default.
• W4379285725 hasAuthorship W4379285725A5033869278 @default.
• W4379285725 hasAuthorship W4379285725A5068044534 @default.
• W4379285725 hasAuthorship W4379285725A5071104146 @default.
• W4379285725 hasAuthorship W4379285725A5074524521 @default.
• W4379285725 hasConcept C121608353 @default.
• W4379285725 hasConcept C126322002 @default.
• W4379285725 hasConcept C207103383 @default.
• W4379285725 hasConcept C2780035454 @default.
• W4379285725 hasConcept C3018890749 @default.
• W4379285725 hasConcept C3020340455 @default.
• W4379285725 hasConcept C44249647 @default.
• W4379285725 hasConcept C512399662 @default.
• W4379285725 hasConcept C535046627 @default.
• W4379285725 hasConcept C60644358 @default.
• W4379285725 hasConcept C71924100 @default.
• W4379285725 hasConcept C75480439 @default.
• W4379285725 hasConcept C86803240 @default.
• W4379285725 hasConcept C98274493 @default.
• W4379285725 hasConcept C99454951 @default.
• W4379285725 hasConceptScore W4379285725C121608353 @default.
• W4379285725 hasConceptScore W4379285725C126322002 @default.
• W4379285725 hasConceptScore W4379285725C207103383 @default.
• W4379285725 hasConceptScore W4379285725C2780035454 @default.
• W4379285725 hasConceptScore W4379285725C3018890749 @default.
• W4379285725 hasConceptScore W4379285725C3020340455 @default.
• W4379285725 hasConceptScore W4379285725C44249647 @default.
• W4379285725 hasConceptScore W4379285725C512399662 @default.
• W4379285725 hasConceptScore W4379285725C535046627 @default.
• W4379285725 hasConceptScore W4379285725C60644358 @default.
• W4379285725 hasConceptScore W4379285725C71924100 @default.
• W4379285725 hasConceptScore W4379285725C75480439 @default.
• W4379285725 hasConceptScore W4379285725C86803240 @default.
• W4379285725 hasConceptScore W4379285725C98274493 @default.
• W4379285725 hasConceptScore W4379285725C99454951 @default.
• W4379285725 hasIssue "16_suppl" @default.
• W4379285725 hasLocation W43792857251 @default.
• W4379285725 hasOpenAccess W4379285725 @default.
• W4379285725 hasPrimaryLocation W43792857251 @default.
• W4379285725 hasRelatedWork W1573843750 @default.
• W4379285725 hasRelatedWork W2388075619 @default.
• W4379285725 hasRelatedWork W2944908478 @default.
• W4379285725 hasRelatedWork W3203879531 @default.
• W4379285725 hasRelatedWork W3207854145 @default.
• W4379285725 hasRelatedWork W4210652229 @default.
• W4379285725 hasRelatedWork W4280510143 @default.
• W4379285725 hasRelatedWork W4300283912 @default.
• W4379285725 hasRelatedWork W4301195367 @default.
• W4379285725 hasRelatedWork W4323533346 @default.
• W4379285725 hasVolume "41" @default.
• W4379285725 isParatext "false" @default.
• W4379285725 isRetracted "false" @default.
• W4379285725 workType "article" @default.